Quarterly report · Q3
4544.TEDINET S100Q5GN
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥201.0bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥272.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥197.9bn | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥23.6bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥36.2bn | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥23.2bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥47.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥35.5bn | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥25.8bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥33.7bn | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥18.8bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥25.5bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥18.8bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥25.5bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥280.3bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥286.6bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥277.0bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥127.2bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥146.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥153.2bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥140.2bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥133.6bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥30.5bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥46.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥30.5bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.2bn | at 2021-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥43.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥19.2bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥55.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥38.4bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥24.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥30.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥19.2bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥10.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥21.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥16.1bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥330.26 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥56.84 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥519.55 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥447.68 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥105.45 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥330.22 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥519.42 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥447.55 | 2021-04-01 → 2021-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 54.6% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.9% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.2% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥6.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥6.2bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥3.3bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥124.9bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥124.7bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥212m |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥2.7bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥61.6bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥55.6bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥5.9bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥23.4bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥20.7bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥20.6bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥15m |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥825m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥207.1bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥201.0bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥6.2bn |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥26.9bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-12-31 | −¥7.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-12-31 | −¥7.2bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-12-31 | −¥775m |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥131.2bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥131.0bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥216m |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥17.7bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥52.1bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥45.2bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥7.0bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥17.8bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥21.8bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥21.7bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥15m |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥1.4bn |
| —segment total | revenue | 2021-04-01 → 2021-12-31 | ¥205.1bn |
| —segment total | revenue external | 2021-04-01 → 2021-12-31 | ¥197.9bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥7.2bn |
| —segment total | segment profit | 2021-04-01 → 2021-12-31 | ¥36.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 479
| Item | Context | Value | Unit |
|---|---|---|---|
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都新宿区西新宿二丁目１番１号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Description of fact that quarterly securities report for first quarter or third quarter presents consolidated statement of cash flows financial information | CurrentYTDDuration | Original text (Japanese)なお、四半期連結財務諸表規則第５条の２第３項により、四半期連結キャッシュ・フロー計算書を作成しております。 | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding reduction entry (text) | CurrentQuarterInstant | Text · Plus | |
| Notes regarding guarantee obligations (text) | CurrentQuarterInstant | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentQuarterInstant | Text · Plus | |
| Notes regarding gain on step acquisitions | CurrentYTDDuration | Original text (Japanese)※１ 段階取得に係る差益は、Fluxus, Inc.の株式の段階取得に伴い発生したものであります。 | |
| Notes regarding loss on valuation of other investments (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |